News Archives
November 26, 2019
Axial Biotherapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference
November 18, 2019
Axial Biotherapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial Evaluating AB-2004 in Patients with Autism Spectrum Disorder
October 18, 2019
Axial Biotherapeutics Presents Preclinical Data on Microbiome – Derived Metabolites Associated with Autism Spectrum Disorder at the Society for Neuroscience 2019 Annual Meeting
October 11, 2019
Axial Biotherapeutics to Participate in 5th Annual BMO Private Company Showcase
July 16, 2019
Axial Biotherapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AB-2004 for Treatment of Gastrointestinal Dysfunction and Associated Behavioral Symptoms of Autism Spectrum Disorder
June 20, 2019
Axial Biotherapeutics Announces $10M Investment from Taiho Ventures to Access Axial’s Expertise in the Gut-Brain Axis
May 31, 2019
Axial Biotherapeutics Announces Publication of Preclinical Data Highlighting the Link Between Human Gut Microbiota and Behavioral Symptoms of Autism Spectrum Disorder in Mouse Models
May 02, 2019
Axial Biotherapeutics Presents New Preclinical Data from AB-2004 Program Demonstrating Reduction of Microbiome-Derived Metabolites in Mouse Models with Autism Spectrum Disorder at the International Society for Autism Research (INSAR) 2019 Annual Meeting